Impact of Administration of Esmolol on Nociception Level-guided Control of Nociception.

Anesthesia Clinical Trial

— ESMONOL  

Official title:

Impact of Continuous Intraoperative Administration of Esmolol on Nociception Level-guided Control of Nociception. The EsmoNOL Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06291363
• Other study ID #: 2024-3612
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: April 4, 2024
• Est. completion date: March 4, 2025

Study information

• Verified date: March 2024
• Source: Ciusss de L'Est de l'Île de Montréal
• Contact: Pascal Laferrière-Langlois
• Phone: +1-819-432-5847
• Email: pascal.laferriere-langlois[@]umontreal.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate esmolol's perfusion impact during induction and maintenance of general anesthesia, using Nociception-Level-guided control of nociception, in adult patients undergoing laparoscopic and lower abdominal surgery, on intraoperative remifentanil consumption and postoperative pain in the Post-Anesthesia Care Unit.

Description:

Opioids are currently the gold standard for perioperative pain control and allow for proper intraoperative hemodynamic stability. However, their use presents several major challenges, as demonstrated by the opioid crisis intensifying over the years in North America and increasingly in Europe. Besides commonly described adverse effects such as postoperative nausea, vomiting, respiratory depression, ileus, or pruritus, opioids are associated with induced hyperalgesia. In this context, several opioid-sparing strategies have been explored. The use of esmolol, a short-acting beta-blocker, can reduce sympathetic stimulation induced by perioperative nociceptive stimuli. Integrated into a multimodal strategy, it reduces the need for intraoperative opioid administration and postoperative analgesic consumption. Concurrently, multiparametric monitoring of nociception via the Nociception-Level Index (NOL index) also allows for a reduction in intraoperative opioids and decreased pain scores in the post anesthesia care unit (PACU).

The aim of this trial will be to explore the combination of these two strategies and assess the impact of continuous esmolol infusion on Nociception-Level-guided intraoperative remifentanil administration in patients under general anesthesia undergoing gynecological or general surgery via laparoscopy or lower abdominal laparotomy.

This single center randomized controlled trial will be conducted in a Canadian academic hospital. Participants aged between 18 and 65 years undergoing gynecological or general surgery by laparoscopy or lower abdominal laparotomy will be included in this study. Induction of general anesthesia will be achieved with propofol in combination with target-controlled infusion (TCI) remifentanil at 3 ng.ml-1 for intubation, then guided by the NOL Index during the procedure. Hypnosis will be maintained by the administration of sevoflurane with a target minimum alveolar concentration (MAC) between 0.7 and 1.2 to sustain a bispectral Index (BIS)between 40 and 60. Intervention group participants will receive esmolol as follows: an initial bolus of 0.5 mg.kg-1 at induction of anesthesia followed by a continuous infusion of 20mcg.kg-1.min-1 until the end of the intervention. A saline solution infusion will be administered to control group participants under the same conditions. The primary outcome will be the amount of remifentanil administered intraoperatively in mcg.kg-1.h-1. Secondary outcomes will include variations in the NOL Index during nociceptive stimuli, average heart rate and blood pressure, the intraoperative doses and time weighted average of norepinephrine (mg); ephedrine (mg), glycopyrrolate (mg) and atropine (mg), the total time and time weighted average of hypotension and or bradycardia during surgery, the time to first analgesic requirement, amount of morphine equivalent consumption for postoperative pain relief in PACU, intensity of pain at rest and under stress, using a verbal rating scale (VRS), from arrival to discharge from PACU.

The main objective of the study is to evaluate the impact of continuous intraoperative infusion of esmolol on intraoperative remifentanil administration in patients undergoing general anesthesia with NOL-guided nociception management.

Secondary objectives are listed below.

Based on a recent unpublished trial recently held at Maisonneuve-Rosemont Hospital focusing on colorectal surgeries, the investigators assumed a mean intraoperative remifentanil consumption of 5.59 mcg.kg-1.h-1 and 7.98, respectively in the intervention and control group, with a combined standard deviation of ± 3.24. This data is aligned with recently published international data. With an alpha risk of 5%, a power of 80.0%, a two-tailed test, and an estimated dropout ratio of 10.0%, it was calculated that 32 participants would be required in each group, to detect a 30% reduction in intraoperative remifentanil administration.

Study duration: 12 months

Study Center: Maisonneuve-Rosemont Hospital, Integrated University Health and Social Services Centre (CIUSSS) de l'Est de l'Ile de Montreal (CEMTL), University of Montreal, Montreal, Quebec, Canada.

Adverse Events: there is very little risk involved with participation in this study, side effects that may be associated with the use of esmolol includes bradycardia and/or hypotension

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 64
• Est. completion date: March 4, 2025
• Est. primary completion date: March 3, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Fully consented, American Society of Anesthesiologists Classification Score 1-3 patients from 18yo to 65yo

• Undergoing laparoscopic surgery associated with sub umbilical mini-laparotomy. Eligible surgeries will be hysterectomy (excluding vaginal approach) and left hemicolectomy, of duration time expected under 180 minutes, under general anesthesia

• No allergy to one of the medications used in this study

Exclusion Criteria:

Contraindication to the use of the study drug (esmolol) is an exclusion criterion :

• Hypotension

• Sinus bradycardia

• Sick sinus syndrome

• Second and third degree A-V block

• Pulmonary hypertension

• Right ventricular failure secondary to pulmonary hypertension

• Decompensated heart failure

• Cardiogenic shock

• Nontreated pheochromocytoma

• Known hypersensitivity to esmolol or any of the inactive ingredients of the product

• Allergy to esmolol or other beta blockers (cross-sensitivity is possible)

• Renal dysfunction

• Airway disease such as asthma or chronic obstructive pulmonary disease

• Thyrotoxicosis

• Myasthenia gravis

• Raynaud's disease or peripheral circulatory disorder

Other situations leading to exclusion :

• Severe mental impairment

• Chronic use of opioids, ß-adrenergic receptors antagonists

• High risk of conversion to laparotomy according to the surgical team (>25%)

Patients will automatically be excluded after recruitment if they withdraw their consent, or if laparoscopy is converted to laparotomy.

Related Conditions & MeSH terms

• Anesthesia
• Nociceptive Pain
• Opioid Use, Unspecified

Intervention

Drug:
• Esmolol Hydrochloride
Patients in the experimental group will receive esmolol during general anesthesia
• Saline
Patients in the standard of care group will receive saline as placebo during general anesthesia

Locations

Country	Name	City	State
Canada	Maisonneuve-Rosemont Hospital - CIUSSS de l'Est de l'Île de Montréal	Montréal-Est	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Ciusss de L'Est de l'Île de Montréal

Country where clinical trial is conducted

Canada, 

References & Publications (15)

Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006 Mar;104(3):570-87. doi: 10.1097/00000542-200603000-00025. — View Citation

Asouhidou I, Trikoupi A. Esmolol reduces anesthetic requirements thereby facilitating early extubation; a prospective controlled study in patients undergoing intracranial surgery. BMC Anesthesiol. 2015 Nov 28;15:172. doi: 10.1186/s12871-015-0154-1. — View Citation

Bergeron C, Brulotte V, Pelen F, Clairoux A, Belanger ME, Issa R, Urbanowicz R, Tanoubi I, Drolet P, Fortier LP, Verdonck O, Fortier A, Espitalier F, Richebe P. Impact of chronic treatment by beta1-adrenergic antagonists on Nociceptive-Level (NOL) index variation after a standardized noxious stimulus under general anesthesia: a cohort study. J Clin Monit Comput. 2022 Feb;36(1):109-120. doi: 10.1007/s10877-020-00626-4. Epub 2021 Jan 4. — View Citation

Bohringer C, Astorga C, Liu H. The Benefits of Opioid Free Anesthesia and the Precautions Necessary When Employing It. Transl Perioper Pain Med. 2020;7(1):152-157. — View Citation

Celebi N, Cizmeci EA, Canbay O. [Intraoperative esmolol infusion reduces postoperative analgesic consumption and anaesthetic use during septorhinoplasty: a randomized trial]. Rev Bras Anestesiol. 2014 Sep-Oct;64(5):343-9. doi: 10.1016/j.bjan.2013.10.013. Epub 2014 Jun 21. Portuguese. — View Citation

Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet. 2019 Apr 13;393(10180):1558-1568. doi: 10.1016/S0140-6736(19)30430-1. — View Citation

Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. Br J Anaesth. 2014 Jun;112(6):991-1004. doi: 10.1093/bja/aeu137. — View Citation

Gelineau AM, King MR, Ladha KS, Burns SM, Houle T, Anderson TA. Intraoperative Esmolol as an Adjunct for Perioperative Opioid and Postoperative Pain Reduction: A Systematic Review, Meta-analysis, and Meta-regression. Anesth Analg. 2018 Mar;126(3):1035-1049. doi: 10.1213/ANE.0000000000002469. — View Citation

Martini CH, Boon M, Broens SJ, Hekkelman EF, Oudhoff LA, Buddeke AW, Dahan A. Ability of the nociception level, a multiparameter composite of autonomic signals, to detect noxious stimuli during propofol-remifentanil anesthesia. Anesthesiology. 2015 Sep;123(3):524-34. doi: 10.1097/ALN.0000000000000757. — View Citation

Paloheimo MP, Sahanne S, Uutela KH. Autonomic nervous system state: the effect of general anaesthesia and bilateral tonsillectomy after unilateral infiltration of lidocaine. Br J Anaesth. 2010 May;104(5):587-95. doi: 10.1093/bja/aeq065. Epub 2010 Mar 30. — View Citation

Renaud-Roy E, Stockle PA, Maximos S, Brulotte V, Sideris L, Dube P, Drolet P, Tanoubi I, Issa R, Verdonck O, Fortier LP, Richebe P. Correlation between incremental remifentanil doses and the Nociception Level (NOL) index response after intraoperative noxious stimuli. Can J Anaesth. 2019 Sep;66(9):1049-1061. doi: 10.1007/s12630-019-01372-1. Epub 2019 Apr 17. — View Citation

Richebe P, Capdevila X, Rivat C. Persistent Postsurgical Pain: Pathophysiology and Preventative Pharmacologic Considerations. Anesthesiology. 2018 Sep;129(3):590-607. doi: 10.1097/ALN.0000000000002238. — View Citation

Sabourdin N, Burey J, Tuffet S, Thomin A, Rousseau A, Al-Hawari M, Taconet C, Louvet N, Constant I. Analgesia Nociception Index-Guided Remifentanil versus Standard Care during Propofol Anesthesia: A Randomized Controlled Trial. J Clin Med. 2022 Jan 11;11(2):333. doi: 10.3390/jcm11020333. — View Citation

Shahiri TS, Richebe P, Richard-Lalonde M, Gelinas C. Description of the validity of the Analgesia Nociception Index (ANI) and Nociception Level Index (NOL) for nociception assessment in anesthetized patients undergoing surgery: a systematized review. J Clin Monit Comput. 2022 Jun;36(3):623-635. doi: 10.1007/s10877-021-00772-3. Epub 2021 Nov 16. — View Citation

Shanthanna H, Ladha KS, Kehlet H, Joshi GP. Perioperative Opioid Administration. Anesthesiology. 2021 Apr 1;134(4):645-659. doi: 10.1097/ALN.0000000000003572. — View Citation

* Note: There are 15 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intra operative remifentanil administration	Quantity of remifentanil in mcg.kg-1.h-1, administered between the first surgical incision and its discontinuation at wound dressing	intraoperative (from T0 = incision until Tend = end of dressing)
Secondary	The NOL Index variation before and after orotracheal intubation and first surgical incision	The NOL Index variation before and after orotracheal intubation and first surgical incision	intraoperative (from T0 = nociceptive stimulation Tend = 3 minutes post stimulation)
Secondary	The mean intraoperative blood pressure and heart rate	The mean intraoperative blood pressure and heart rate during surgery	intraoperative (from T0 = incision until Tend = end of dressing)
Secondary	doses and time weighted of norepinephrine (mg); ephedrine (mg), glycopyrrolate (mg) and atropine (mg)	doses and time weighted average of norepinephrine (mg); ephedrine (mg), glycopyrrolate (mg) and atropine (mg)	intraoperative (from T0 = incision until Tend = end of dressing)
Secondary	Total time with NOL value above > 25	Total time and time weighted average with NOL value above > 25	intraoperative (from T0 = incision until Tend = end of dressing)
Secondary	The total time and time weighted average of hypotension and/or bradycardia	The total time and time weighted average of hypotension (< 20% of the baseline values of the pre-anesthesia mean arterial pressure (MAP) and/or bradycardia (HR < 60 beats/min, or HR < 50 beats/min for a profound bradycardia)) during surgery	intraoperative (from T0 = incision until Tend = end of dressing)
Secondary	The time to first analgesic requirement in PACU	The time to first analgesic requirement in PACU	postoperative (from T0 = PACU arrival until Tend = PACU discharge)
Secondary	The amount of morphine equivalent consumption	The amount of morphine equivalent consumption for postoperative pain relief in the post anesthesia care unit (PACU) in both groups	postoperative (from T0 = PACU arrival until Tend = PACU discharge)
Secondary	The intensity of pain at rest and under stress	The intensity of pain at rest and under stress, using a verbal rating scale from 0 to 10 : 0 being no pain, and 10 the worst pain imaginable. I'll be assessed every 30 minutes from arrival to discharge from PACU	postoperative (from T0 = PACU arrival until Tend = PACU discharge)
Secondary	Postoperative nausea and vomiting (PONV) and antiemetics use	Postoperative outcomes such as postoperative nausea and vomiting (PONV) and amount of antiemetics used in PACU	postoperative (from T0 = PACU arrival until Tend = PACU discharge)
Secondary	The time spent in PACU	time spent in PACU (in minutes)	postoperative (from T0 = PACU arrival until Tend = PACU discharge)